Redhawk Wealth Advisors Inc. Purchases 153 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Redhawk Wealth Advisors Inc. lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,339 shares of the pharmaceutical company’s stock after purchasing an additional 153 shares during the quarter. Redhawk Wealth Advisors Inc.’s holdings in Vertex Pharmaceuticals were worth $2,150,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Northwest Investment Counselors LLC purchased a new position in Vertex Pharmaceuticals in the 3rd quarter worth $25,000. Highline Wealth Partners LLC purchased a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at about $27,000. Dunhill Financial LLC grew its position in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 24 shares during the last quarter. Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $33,000. Finally, Truvestments Capital LLC bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth approximately $35,000. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Bank of America dropped their target price on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a report on Thursday, December 19th. HC Wainwright cut their target price on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a research note on Friday, December 20th. Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $500.00 to $550.00 in a research report on Monday, December 9th. Citigroup began coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 14th. They issued a “buy” rating and a $575.00 target price on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $490.38.

Vertex Pharmaceuticals Trading Up 3.1 %

VRTX opened at $424.26 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The firm’s fifty day moving average is $445.93 and its 200 day moving average is $467.13. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same quarter in the prior year, the company posted $3.67 earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.